Study type: In vivo/preclinical · Status: Evidence verified by machine against declared source

Cerebrolysin Attenuates Exacerbation of Neuropathic Pain, Blood-spinal Cord Barrier Breakdown and Cord Pathology Following Chronic Intoxication of Engineered Ag, Cu or Al (50-60 nm) Nanoparticles.

Neurochemical research · 2023

Study scale: Values are Mean ± SD of 6–8 rats at each point.

Product or molecular entity relationships

Cerebrolysin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Public plain-language summary

The published text is limited to the declared source and preserves reported uncertainty. It does not establish efficacy, safety, suitability, or evidence strength.

Research question

Our laboratory explored novel potential therapeutic strategies using a suitable composition of neurotrophic factors and active peptide fragments-Cerebrolysin (Ever Neuro Pharma, Austria) in alleviating neuropathic pain induced spinal cord pathology in a rat model.

Study design

Not reported in the declared source.

Participants or experimental system

In one group of rats cerebrolysin (2.5 or 5 ml/kg, i.v.) was administered once daily after 2 weeks until sacrifice (4, 8 and 10 weeks).

Study scale

Values are Mean ± SD of 6–8 rats at each point.

Intervention or exposure

Ag, Cu and Al NPs (50 mg/kg, i.p.) were delivered once daily for 1 week.

Comparator

In sham group, the left spinal nerves L5 and L6 were exposed identically but not ligated.

Outcomes examined

The levels of cytokines were also restored near normal levels with cerebrolysin treatment.

Key findings

Neuropathic pain is associated with abnormal sensations and/or pain induced by non-painful stimuli, i.e., allodynia causing burning or cold sensation, pinching of pins and needles like feeling, numbness, aching or itching.

Limitations and uncertainty

Thus, further studies are needed to regulate the microenvironment of the central nervous system (CNS) by suitable drugs to minimize sufferings of these victims from excessive neuropathic pain syndrome.

Product relevance and evidence boundary

This record is a published study, held here with its citation and review status. It is not a statement that any catalog item is effective, safe, or suitable for any use, and nothing in it is a dose or a protocol.

Evidence verified by machine against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.